Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19098294 | Selective Serotonin Receptor Modulators and Methods of Making and Using the Same | April 2025 | January 2026 | Allow | 9 | 2 | 1 | Yes | No |
| 18719054 | MANUFACTURING OF DIMERIC CONTRAST AGENT | June 2024 | July 2025 | Allow | 13 | 1 | 0 | Yes | No |
| 18671217 | RUFINAMIDE FOR USE IN THE TREATMENT OF MYOTONIA | May 2024 | September 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18657123 | N-SUBSTITUTED TETRAHYDROTHIENOPYRIDINE DERIVATIVES AND USES THEREOF | May 2024 | February 2025 | Allow | 9 | 1 | 0 | Yes | No |
| 18643431 | COMPOSITIONS AND METHODS FOR TREATING CANNABINOID HYPEREMESIS SYNDROME | April 2024 | November 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18623327 | SUSTAINED RELEASE OLANZAPINE FORMULATIONS | April 2024 | August 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18622139 | Formulation of Resiniferatoxin | March 2024 | May 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18600974 | HETEROCYCLIC PDK1 INHIBITORS FOR USE TO TREAT CANCER | March 2024 | June 2025 | Abandon | 15 | 0 | 1 | No | No |
| 18430855 | OPHTHALMIC SOLUTION OF DIFLUPREDNATE | February 2024 | April 2025 | Allow | 14 | 2 | 0 | Yes | No |
| 18403100 | USE OF METFORMIN AND ANALOGS THEREOF TO REDUCE RAN PROTEIN LEVELS IN THE TREATMENT OF NEUROLOGICAL DISORDERS | January 2024 | January 2026 | Allow | 24 | 2 | 1 | Yes | No |
| 18530663 | USE OF PHOSPHOINOSITIDE 3-KINASE INHIBITORS FOR TREATMENT OF VASCULAR MALFORMATIONS | December 2023 | April 2025 | Abandon | 16 | 1 | 0 | No | No |
| 18531259 | COMPOSITIONS COMPRISING 15-OHEPA AND METHODS OF USING THE SAME | December 2023 | June 2025 | Abandon | 19 | 2 | 0 | Yes | No |
| 18386101 | COMPOSITIONS AND METHODS FOR INCREASING EFFICIENCY OF CARDIAC METABOLISM | November 2023 | February 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18378480 | EFFICIENT ANTI-BACTERIAL HYDROXY ACID ESTER OLIGOMER | October 2023 | March 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18462080 | COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF | September 2023 | November 2025 | Allow | 27 | 1 | 1 | Yes | No |
| 18461253 | FUSED 1,4-DIHYDRODIOXIN DERIVATIVES AS INHIBITORS OF HEAT SHOCK TRANSCRIPTION FACTOR 1 | September 2023 | July 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18456612 | COMPOSITIONS, GELS AND FOAMS WITH RHEOLOGY MODULATORS AND USES THEREOF | August 2023 | February 2025 | Abandon | 17 | 0 | 1 | No | No |
| 18450379 | CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4-OXAZEPANE-2-CARBOXAMIDES FOR TREATING BRONCHIECTASIS | August 2023 | March 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18233398 | CALCIUM SUCCINATE MONOHYDRATE FORMULATION | August 2023 | October 2024 | Abandon | 14 | 2 | 0 | No | No |
| 18447059 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO AGING | August 2023 | December 2024 | Abandon | 17 | 1 | 1 | No | No |
| 18231977 | COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND NON-ALCOHOLIC STEATOHEPATITIS | August 2023 | July 2025 | Abandon | 23 | 1 | 1 | No | No |
| 18363328 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | August 2023 | February 2025 | Allow | 18 | 1 | 0 | Yes | No |
| 18345623 | TOPICAL COMPOSITIONS COMPRISING BIMATOPROST AND METHODS FOR STIMULATING HAIR GROWTH THEREWITH | June 2023 | March 2025 | Abandon | 20 | 1 | 0 | No | No |
| 18340308 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | June 2023 | January 2025 | Allow | 19 | 1 | 0 | Yes | No |
| 18258514 | (2S)-2-Aminopentanethioic S-acid for use as medicament and in therapy of amyotrophic lateral sclerosis | June 2023 | September 2025 | Allow | 27 | 0 | 0 | Yes | No |
| 18210217 | CO-CRYSTALS | June 2023 | December 2024 | Allow | 18 | 0 | 1 | Yes | No |
| 18210046 | COMBINATION THERAPY FOR THE TREATMENT OF TINNITUS AND OTHER MEDICAL CONDITIONS | June 2023 | October 2024 | Allow | 16 | 1 | 1 | Yes | No |
| 18200517 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | May 2023 | September 2025 | Abandon | 27 | 2 | 0 | No | No |
| 18144593 | TREATMENT OF B-CELL MALIGNANCIES BY A COMBINATION JAK AND PI3K INHIBITORS | May 2023 | November 2025 | Abandon | 30 | 2 | 1 | Yes | No |
| 18302691 | (2S)-1-[4-(3,4-DICHLOROPHENYL)PIPERIDIN-1-YL]-3-[2-(5-METHYL-1,3,4-OXADIAZOL-2-YL)BENZO[B]FURAN-4-YLOXY] PROPAN-2-OL OR ITS METABOLITE FOR TREATING ANXIETY DISORDERS | April 2023 | June 2025 | Abandon | 26 | 2 | 0 | No | No |
| 18246861 | TOPICAL RUXOLITINIB FOR TREATING LICHEN PLANUS | March 2023 | March 2026 | Abandon | 35 | 3 | 0 | No | No |
| 18120484 | 4-(PHENOXYALKYL)THIO)-PHENOXYACETIC ACIDS AND ANALOGS | March 2023 | March 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18176008 | Use of Sodium Octanoate in Preparation of Medicine for Improving the Efficacy of Cardiopulmonary Resuscitation and Post-Resuscitation Multiple Organ Dysfunction | February 2023 | October 2025 | Allow | 32 | 1 | 0 | Yes | No |
| 18170379 | COMPOSITIONS AND METHODS FOR MOOD ENHANCEMENT | February 2023 | March 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18163811 | STABLE PHARMACEUTICAL COMPOSITIONS OF HYDROXYUREA | February 2023 | March 2025 | Abandon | 25 | 3 | 1 | Yes | No |
| 18158889 | ANTIMICROBIAL COMPOSITIONS CONTAINING CATIONIC ACTIVE INGREDIENTS | January 2023 | August 2024 | Allow | 19 | 2 | 1 | Yes | No |
| 18095498 | PHOSPHOLIPID COMPOSITIONS FOR TREATING INFECTIONS AND INFLAMMATION | January 2023 | December 2024 | Abandon | 23 | 1 | 1 | No | No |
| 18001556 | Composition and Method for Treating Chronic Pain | December 2022 | January 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18077832 | COMPOSITIONS AND METHODS OF USE OF GAMMA-KETOALDEHYDE SCAVENGERS FOR TREATING, PREVENTING OR IMPROVING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD), NASH, ALD OR CONDITIONS RELATED TO THE LIVER | December 2022 | April 2025 | Allow | 28 | 1 | 1 | No | No |
| 17918542 | TREATMENT OF VIRAL PATHOLOGIES WITH EXOGENOUS KETONES | October 2022 | February 2026 | Abandon | 40 | 0 | 1 | No | No |
| 17897116 | NOVEL ANTHRANILIC AMIDES AND THE USE THEREOF | August 2022 | November 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17883245 | PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) INHIBITOR AND METHOD OF USE | August 2022 | April 2025 | Allow | 32 | 2 | 1 | Yes | No |
| 17810044 | LIPIDS WITH ODD NUMBER OF CARBON ATOMS AND THEIR USE AS PHARMACEUTICAL COMPOSITION OR NUTRITIONAL SUPPLEMENT | June 2022 | December 2025 | Allow | 41 | 0 | 1 | Yes | No |
| 17789631 | DOSAGE REGIME WITH ESKETAMINE FOR TREATING MAJOR DEPRESSIVE DISORDER | June 2022 | December 2024 | Allow | 29 | 2 | 0 | Yes | No |
| 17839202 | FUSED CYCLOOCTYNE COMPOUNDS AND THEIR USE IN METAL-FREE CLICK REACTIONS | June 2022 | September 2024 | Allow | 27 | 2 | 0 | Yes | No |
| 17755720 | SOLID DISPERSION OF URSOLIC ACID AND POTASSIUM SALT | May 2022 | December 2025 | Allow | 43 | 1 | 1 | Yes | No |
| 17642068 | AVOCATIN B FOR THE TREATMENT OF DISEASES AND CONDITIONS | March 2022 | July 2025 | Allow | 40 | 0 | 1 | Yes | No |
| 17640411 | TREATMENT OF FRAGILE X SYNDROME WITH IBUDILAST IN COMBINATION WITH METFORMIN, CANNBIDIOL, SERTRALINE OR QUERCETIN | March 2022 | December 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17638614 | HUMECTANT AND/OR BUFFERED STARCH COMPOSITIONS AND USE IN ORAL CARE SUCH AS TREATING XEROSTOMIA | February 2022 | October 2025 | Abandon | 44 | 0 | 1 | No | No |
| 17669425 | USE OF LOW DOSE EMETINE FOR INHIBITION OF HUMAN CYTOMEGALOVIRUS (HCMV) | February 2022 | September 2024 | Allow | 31 | 1 | 1 | Yes | No |
| 17630652 | PHARMACEUTICAL COMPOSITION COMPRISING TRIMETHOBENZAMIDE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AS ACTIVE INGREDIENT FOR PREVENTING OR TREATING NEUROPATHIC PAIN | January 2022 | December 2025 | Abandon | 47 | 1 | 0 | No | No |
| 17628691 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | January 2022 | January 2026 | Abandon | 48 | 1 | 1 | No | No |
| 17556793 | METHODS OF TREATING TOBACCO SMOKING ADDICTION, AND TREATING NICOTINE AND TOBACCO SMOKING ADDICTION | December 2021 | September 2025 | Abandon | 45 | 0 | 1 | No | No |
| 17555898 | INHIBITION OF BETA-2 NICOTINIC ACETYLCHOLINE RECEPTORS TO TREAT ALZHEIMER'S DISEASE PATHOLOGY | December 2021 | April 2025 | Abandon | 40 | 3 | 0 | No | No |
| 17616628 | METHOD FOR TREATING OR PREVENTING SACCHARIDE-RELATED DISEASES OR DISORDERS | December 2021 | February 2026 | Abandon | 50 | 0 | 1 | No | No |
| 17457420 | METHOD FOR TREATING ASTHMA | December 2021 | October 2025 | Abandon | 46 | 2 | 0 | Yes | No |
| 17531379 | MODULATING AFFERENT SIGNALS TO TREAT MEDICAL CONDITIONS | November 2021 | August 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17611539 | 3-ARYLOXY-3-FIVE-MEMBERED HETEROARYL PROPYLAMINE COMPOUND, AND CRYSTAL FORM AND USE THEREOF | November 2021 | October 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17610417 | SUBSTITUTED FLUORINE-CONTAINING IMIDAZOLE SALT COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | November 2021 | February 2026 | Allow | 51 | 2 | 1 | Yes | No |
| 17521813 | Arginine Silicate For Periodontal Disease | November 2021 | July 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17606125 | NOVEL PHARMACEUTICAL COMPOSITION | October 2021 | May 2025 | Abandon | 42 | 1 | 0 | No | No |
| 17510375 | Efficient anti-bacterial hydroxy acid ester oligomer | October 2021 | November 2024 | Abandon | 37 | 2 | 0 | No | No |
| 17604618 | LIQUID SILDENAFIL CITRATE COMPOSITIONS | October 2021 | May 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17369268 | ANAPLEROTIC AGENTS FOR TREATMENT OF DISORDERS OF PROPIONATE AND LONG CHAIN FAT METABOLISM | July 2021 | March 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17289606 | PHARMACEUTICAL COMBINATIONS FOR THE TREATMENT OF PAIN | April 2021 | April 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17231674 | NOVEL COMPOSITIONS FOR THE TREATMENT OF INFLAMMATORY DISEASES | April 2021 | November 2025 | Abandon | 55 | 2 | 1 | No | No |
| 17230840 | INHIBITION OF AUTOPHAGY USING PHOSPHOLIPASE A2 INHIBITORS | April 2021 | February 2025 | Abandon | 46 | 2 | 1 | No | No |
| 17223096 | STABLE READY TO USE CYCLOPHOSPHAMIDE LIQUID FORMULATIONS | April 2021 | April 2025 | Allow | 48 | 3 | 0 | No | No |
| 17279732 | DERIVATIVE OF SARSASAPOGENIN, PHARMACEUTICAL COMPOSITION AND USE THEREOF | March 2021 | June 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17279763 | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | March 2021 | November 2025 | Abandon | 56 | 2 | 1 | No | No |
| 17274725 | COMBINED SIROLIMUS AND NINTEDANIB THERAPY FOR VASCULAR LESIONS AND HEREDITARY HEMORRHAGIC TELANGIECTASIA | March 2021 | November 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17191084 | Methods and Compositions for Treatment of Asthma or Parkinson's Disease | March 2021 | January 2025 | Abandon | 47 | 1 | 1 | No | No |
| 17103327 | NEW USE | November 2020 | December 2025 | Abandon | 60 | 4 | 1 | Yes | No |
| 17099664 | METHODS OF TREATING TRANSPLANT REJECTION | November 2020 | September 2025 | Abandon | 58 | 2 | 1 | No | Yes |
| 17097080 | COMPOUNDS FOR THE TREATMENT OF CANCER | November 2020 | April 2025 | Allow | 53 | 2 | 1 | Yes | No |
| 16949603 | METHOD OF TREATING TEMPOROMANDIBULAR JOINT DISORDERS | November 2020 | October 2024 | Abandon | 47 | 0 | 1 | No | No |
| 17086198 | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF CONDITIONS RELATED TO AGING | October 2020 | November 2025 | Abandon | 60 | 5 | 1 | Yes | No |
| 17031642 | USE OF 2-HYDROXYBENZYLAMINE FOR THE TREATMENT OF SYSTEMIC LUPUS | September 2020 | November 2024 | Abandon | 49 | 4 | 0 | Yes | No |
| 16996401 | METHODS OF TREATING OSTEONECROSIS WITH LLP2A-BISPHOSPHONATE COMPOUNDS | August 2020 | November 2025 | Allow | 60 | 6 | 1 | Yes | No |
| 16963672 | SYNERGISTIC PHARMACEUTICAL COMBINATION OF THE ACTIVE ENANTIOMER S-KETOROLAC TROMETHAMINE AND TRAMADOL CHLORHYDRATE | July 2020 | December 2024 | Abandon | 53 | 6 | 0 | Yes | No |
| 16852225 | METHODS OF TREATING OCULAR CONDITIONS | April 2020 | January 2025 | Abandon | 57 | 3 | 1 | No | No |
| 16757312 | COMPOSITIONS AND METHODS FOR BROAD-SPECTRUM ANTIVIRAL THERAPY | April 2020 | September 2024 | Allow | 53 | 3 | 1 | Yes | Yes |
| 16641145 | ASYMMETRIC SYNTHESIS AND USES OF COMPOUNDS IN DISEASE TREATMENTS | February 2020 | April 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16791683 | METHODS OF REDUCING THE RISK OF A CARDIOVASCULAR EVENT IN A STATIN-TREATED SUBJECT BY INCREASING SERUM AND PLASMA EPA AND DPA LEVELS | February 2020 | December 2025 | Abandon | 60 | 6 | 1 | No | No |
| 16630114 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | January 2020 | January 2025 | Allow | 60 | 6 | 0 | Yes | No |
| 16590478 | IN SITU GENERATION OF PEROXYCARBOXYLIC ACIDS AT ALKALINE pH, AND METHODS OF USE THEREOF | October 2019 | December 2025 | Allow | 60 | 9 | 1 | Yes | No |
| 16490655 | Methods of Treating Conditions Associated with Leaky Gut Barrier | September 2019 | December 2024 | Abandon | 60 | 4 | 1 | No | No |
| 16347755 | USE OF 2-HYDROXYBENZYLAMINE IN THE TREATMENT AND PREVENTION OF PULMONARY HYPERTENSION | May 2019 | May 2025 | Abandon | 60 | 5 | 1 | Yes | Yes |
| 16225772 | THERAPEUTIC AGENT FOR BILE DUCT CANCER | December 2018 | October 2019 | Allow | 10 | 1 | 0 | No | No |
| 16300935 | TREATMENT OF MINIERE'S DISEASE | November 2018 | June 2025 | Allow | 60 | 4 | 1 | Yes | Yes |
| 16088866 | USE OF BIOMARKERS ASSOCIATED WITH LINE-1 | September 2018 | August 2025 | Abandon | 60 | 6 | 1 | Yes | No |
| 16069706 | USE OF LONG-TERM FASTING MIMICKING AS DIETARY TREATMENT FOR MULTIPLE MYELOMA AND OTHER CANCERS | July 2018 | July 2025 | Abandon | 60 | 4 | 1 | No | Yes |
| 16067994 | INHIBITORS OF ATAXIA-TELANGIECTASIA MUTATED AND RAD3-RELATED PROTEIN KINASE (ATR) FOR USE IN METHODS OF TREATING CANCER | July 2018 | October 2024 | Allow | 60 | 6 | 1 | Yes | No |
| 15978854 | PHARMACEUTICAL COMPOSITION COMPRISING AMORPHOUS LENALIDOMIDE AND AN ANTIOXIDANT | May 2018 | March 2019 | Allow | 11 | 1 | 1 | Yes | No |
| 15568025 | NOVEL COMPOUNDS | October 2017 | May 2019 | Allow | 19 | 1 | 1 | Yes | No |
| 15547139 | THERAPEUTIC AGENT FOR BILE DUCT CANCER | July 2017 | September 2018 | Allow | 14 | 1 | 1 | Yes | No |
| 15642899 | OXAZOLINE AND ISOXAZOLINE DERIVATIVES AS CRAC MODULATORS | July 2017 | January 2019 | Allow | 18 | 2 | 1 | Yes | No |
| 15514259 | AQUEOUS COMPOSITION CONTAINING RIPASUDIL, OR A SALT, OR A SOLVATE THEREOF | March 2017 | March 2019 | Allow | 24 | 3 | 0 | No | No |
| 15217301 | FORMULATIONS FOR SOLUBILIZING HORMONES | July 2016 | February 2019 | Allow | 30 | 3 | 1 | Yes | No |
| 14913135 | AMIDE DERIVATIVES AS LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | February 2016 | May 2018 | Allow | 27 | 1 | 2 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner NEAGU, IRINA.
With a 33.3% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 18.8% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner NEAGU, IRINA works in Art Unit 1629 and has examined 116 patent applications in our dataset. With an allowance rate of 77.6%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 30 months.
Examiner NEAGU, IRINA's allowance rate of 77.6% places them in the 45% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by NEAGU, IRINA receive 2.01 office actions before reaching final disposition. This places the examiner in the 52% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by NEAGU, IRINA is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +55.2% benefit to allowance rate for applications examined by NEAGU, IRINA. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 27.7% of applications are subsequently allowed. This success rate is in the 49% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.
This examiner enters after-final amendments leading to allowance in 32.4% of cases where such amendments are filed. This entry rate is in the 47% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
This examiner withdraws rejections or reopens prosecution in 76.9% of appeals filed. This is in the 68% percentile among all examiners. Of these withdrawals, 80.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows above-average willingness to reconsider rejections during appeals. The mandatory appeal conference (MPEP § 1207.01) provides an opportunity for reconsideration.
When applicants file petitions regarding this examiner's actions, 31.2% are granted (fully or in part). This grant rate is in the 18% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 1% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 1% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.